
Opinion|Videos|December 6, 2024
Timeline of Enfortumab Vedotin in UC: From Previously Treated UC to Frontline Therapy
Author(s)Thomas Powles MBBS, MRCP, MD
Thomas Powles, MBBS, MRCP, MD, discusses how antibody-drug conjugates have demonstrated improvement over chemotherapy. Data from the EV-301 trial shows that the antibody-drug conjugate enfortumab vedotin decreased the risk of death by 30% versus chemotherapy. Later trial data showed that treatment using enfortumab vedotin plus pembrolizumab (EV+P) reduced the risk of patient death by 53%.
Advertisement
Episodes in this series

Advertisement
Related to this article

Cretostimogene improved RFS after tumor resection in PIVOT-006, supporting a planned FDA submission for NMIBC.

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
Dr Cortes on the Rationale Behind the OPTIC Trial in CML
4
Localized Prostate Cancer 2026 UPDATE: PSMA PET, ARPI Strategies, and New Trials Reshape Localized Management
5


